Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma. by Syed, N et al.
Epigenetic status of argininosuccinate synthetase and
argininosuccinate lyase modulates autophagy and cell
death in glioblastoma
N Syed*,1, J Langer1, K Janczar1, P Singh1, C Lo Nigro2, L Lattanzio2, HM Coley3, E Hatzimichael4, J Bomalaski5, P Szlosarek6,
M Awad7, K O’Neil 7, F Roncaroli1 and T Crook8
Arginine deprivation, either by nutritional starvation or exposure to ADI-PEG20, induces adaptive transcriptional upregulation of
ASS1 and ASL in glioblastoma multiforme ex vivo cultures and cell lines. This adaptive transcriptional upregulation is blocked by
neoplasia-specific CpG island methylation in either gene, causing arginine auxotrophy and cell death. In cells with methylated
ASS1 or ASL CpG islands, ADI-PEG20 initially induces a protective autophagic response, but abrogation of this by chloroquine
accelerates and potentiates cytotoxicity. Concomitant methylation in the CpG islands of both ASS1 and ASL, observed in a
subset of cases, confers hypersensitivity to ADI-PEG20. Cancer stem cells positive for CD133 and methylation in the ASL CpG
island retain sensitivity to ADI-PEG20. Our results show for the first time that epigenetic changes occur in both of the two key
genes of arginine biosynthesis in human cancer and confer sensitivity to therapeutic arginine deprivation. We demonstrate that
methylation status of the CpG islands, rather than expression levels per se of the genes, predicts sensitivity to arginine
deprivation. Our results suggest a novel therapeutic strategy for this invariably fatal central nervous system neoplasm for which
we have identified robust biomarkers and which overcomes the limitations to conventional chemotherapy imposed by the blood/
brain barrier.
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Glioblastoma multiforme (GBM) is the most common primary
human malignant brain tumour and is among the most lethal of
all cancers.1 Despite advances in surgical management and
radiotherapy, and development of temozolomide, the median
survival for patients is 12–16 months.2,3 The unfavourable
prognosis in this disease is strongly correlated to the intrinsic
apoptosis resistance of GBM.4,5 Disease recurrence after
treatment is mechanistically linked to the presence of chemo-/
radio-resistant CD133þ cancer stem cells (CSCs).6 A further
barrier to effective therapy of GBM is the presence of the
blood/brain barrier, which limits access of chemotherapy to
the central nervous system. These considerations clearly
underline the urgent need for novel therapeutic approaches.
GBM cells are less sensitive to apoptosis,4 yet less resistant to
therapies that induce autophagy.7–9 Temozolomide, the most
active agent in treating GBM, exerts cytotoxicity by inducing
autophagic cell death.10 Autophagy is a non-apoptotic route of
programmed cell death involving the formation of large
double-membrane autophagic vacuoles termed autophago-
somes11,12 to degrade and recycle long-lived organelles and
proteins by merging with lysosomes to form autolysosomes.
Autophagy has a critical role in cellular survival during periods
of starvation, but when stress conditions are excessive,
autophagy becomes a cellular suicide pathway. As such,
autophagy is initially an adaptive response to ensure survival
but beyond a certain threshold may mediate a form of non-
caspase-mediated cell death.
Tumour cells have a high requirement for arginine. This
semi-essential amino acid is synthesized from citrulline via the
urea cycle enzymes argininosuccinate synthetase (ASS)
and argininosuccinate lyase (ASL).13 In a subset of
human cancers, ASS expression is lost rendering them
highly sensitive to deprivation of arginine by pegylated
arginine deiminase (ADI-PEG20).14–21 ADI-PEG20 induces
autophagic cell death in melanoma and in prostate carci-
noma.18,22 ASS and ASL are tightly coupled and upregulated
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in activated rat microglia,23,24 implying that both genes are
dynamically controlled according to cellular stresses. So far,
no reports of ASL-negative cancers have been documented.
Previous studies have identified a number of genes subject
to methylation-dependent transcriptional silencing in high-
grade brain tumours.25–27 To seek additional epigenetically
regulated genes in GBM, we performed methylation reversal
and micro-array analysis in GBM cell lines. Here, we describe
the identification and characterization of the two key enzymes
in arginine biosynthesis, ASS1 and ASL, as epigenetically
regulated genes in GBM, and we demonstrate that epigenetic
changes in these changes modulate cellular sensitivity to
therapeutic autophagy.
Results
Methylation reversal identifies novel methylated genes
in GBM. We used 5-Aza-20-deoxycytidine (50AZA) to
reverse transcriptional silencing in the GAMG GBM cell line.
mRNAs upregulated by demethylation were identified by
micro-array analysis. The mRNA of 47 genes was upregu-
lated at least twofold by 50AZA and of 791 genes at least
1.4-fold. We selected 10 genes and confirmed upregulation
by 50AZA for 7 of them (Figure 1a). Among the genes
upregulated by 50AZA in GAMG cells was ASS1, which
contains a CpG island in the 50 regulatory sequences of the
gene (see Supplementary Figure S1 for map of CpG island,
including location of primers). This gene encodes ASS, the
enzyme catalysing the rate-limiting step in arginine biosynth-
esis. Using quantitative PCR (qPCR) and western blotting,
we confirmed upregulation of ASS1 mRNA by 50AZA in the
GAMG cell line but not in the 42MG cell line (Figure 1b).
Using methylation-specific PCR (MSP), we confirmed that
the increased expression of ASS1 in GAMG following 50AZA
is accompanied by a decrease in CpG island methylation that
does not occur in 42MG (Figure 1b).
Silencing of ASS1 in primary cultures of GBM. To
investigate in detail the potential epigenetic regulation of
ASS1, we established 22 primary GBM cultures from tissue
obtained at first surgical debulking of patients in our clinical
practice. These early passage cultures were tested for
expression and methylation of ASS1. Downregulation of
ASS1 mRNA and protein was observed in 8/22 cases, results
are shown for 10 cases (Figure 1c). Using MSP and
pyrosequencing, all cases with ASS1 methylation had
downregulation of ASS1 mRNA (GBM 31, 53 and 59).
However, in some cases, ASS1 mRNA was downregulated
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Figure 1 Methylation-dependent transcriptional silencing of ASS1 in GBM. (a) Expression of novel candidate genes is upregulated by demethylation. The figure shows
qPCR analysis of the indicated genes in GAMG cells treated (black) or untreated (clear) with 50AZA. Experiments were performed in triplicate and data shown are mean fold
increases (þ / 1 S.D.) in 50AZA-treated cells relative to control cells treated with dimethylsulphoxide. (b) 50AZA upregulates ASS1 in GAMG but not 42MG cells. The top
panel shows qPCR, the middle panel MSP and the bottom panel western blot analysis of ASS in GAMG and 42MG cells with and without exposure to 50AZA as indicated. Actin
is used as a loading control for the western blot. (c) qPCR and western blot analysis of ASS1 in primary GBM explants. qPCR was performed in triplicate and data shown are
expression relative to GBM 7 (þ / 1 S.D.). (d) MSP analysis of ASS1 CpG island in primary GBM explants. The figure shows unmethylated (U) and methylated (M) reactions
for each case. Also shown are control U and M DNA samples modified in parallel with the experimental DNA samples. (e) Pyrosequencing analysis of ASS1 CpG island in
primary GBM explants. The level of methylation in individual CpG dinucleotides is indicated by the intensity of shading as shown
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but without detectable methylation in the CpG island (GBM 6,
27, 25 and 41; Figures 1d and e).
ASL is silenced in primary GBM. ASS catalyses the
rate-limiting step in arginine biosynthesis prompting us to ask
whether expression of ASL, the next enzyme in the arginine
biosynthetic pathway, is also downregulated in GBM. As no
antibodies recognizing ASL protein exist, we analysed
expression of ASL using qPCR. Downregulation of ASL
mRNA was observed in 5/22 primary GBM cultures, results
are shown for 10 primary cultures (Figure 2a). As with ASS1,
there is a CpG island in the regulatory sequences of ASL
(Supplementary Figure S1). Using MSP and pyrosequen-
cing, we showed that each of the primary GBM with
downregulation of ASL was methylated in the ASL CpG
island (Figures 2b and c). To confirm the role of CpG island
methylation, we treated cells with AZA and observed
upregulation of ASL in GBM 59 (CpG island methylated)
but no effect on ASL levels in GBM 6 (CpG island
unmethylated). Following AZA, there was a reduction in
CpG island methylation in GBM 59 (Figure 2d).
As was observed for ASS1, there were cases in which ASL
mRNA was downregulated but without detectable methylation
in the CpG island (GBM 16 and 41).
Methylation abrogates adaptive transcriptional
upregulation of ASS1 and ASL and confers arginine
auxotrophy. As ASS1 and ASL are key enzymes in the
biosynthesis of arginine, we tested the effects of arginine
deprivation on the growth of primary GBM cultures using the
enzyme ADI-PEG20. We first performed a detailed dose
response analysis and showed that the presence of CpG
island methylation in either ASS1 or ASL CpG island was
associated with sensitivity to the anti-proliferative effects of
ADI-PEG20 (GBM 31, 27), whereas cells in which the CpG
islands of ASS1 and ASL were unmethylated were insensi-
tive to ADI-PEG20 (GBM 16) (Figure 3c and Supplementary
Table S2). Cells with methylation in both CpG islands were
hypersensitive to the drug, with complete inhibition of growth
at a concentration of 0.06mg/ml (GBM 59) (Figure 3c). For
analysis of ASS1 and ASL gene expression, qPCR and
western blotting were performed 48 h post treatment. ADI-
PEG20 induced robust upregulation of ASS1 and ASL mRNA
and ASS protein in unmethylated lines as shown in Figures
3a and b, respectively. This adaptive upregulation was
absent in cells with CpG island methylation, but upregulation
was readily induced in these cells by 50AZA. These results
suggest that CpG island methylation in ASS and ASL, rather
than absolute expression levels per se, is the critical
determinant of sensitivity to ADI-PEG20.
To confirm these results, a panel of GBM cell lines were
similarly tested. We confirmed that both ASS1 and ASL are
subject to methylation-dependent transcriptional silencing
(Supplementary Figure S2) and that CpG island methylation
is a critical determinant of sensitivity to ADI-PEG20
(Supplementary Figure S3 and Supplementary Table S2).
Knock down confirms the role of ASS1 in ADI-PEG20
sensitivity. To further verify the role of ASS1 in sensitivity to
ADI-PEG20, we generated stable knockdown cells of ASS1
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Figure 2 Methylation-dependent transcriptional silencing of ASL. (a) qPCR analysis of ASL in primary GBM explants. qPCR was performed in triplicate and data shown
are expression relative to GBM 6 (þ / 1 SD). (b) MSP analysis of ASL CpG island in primary GBM explants. The figure shows unmethylated (U) and methylated (M)
reactions for each case. Also shown are control U and M DNA samples modified in parallel with the experimental DNA samples. (c) Pyrosequencing analysis of ASL CpG
island in primary GBM explants. The level of methylation in individual CpG dinucleotides is indicated by the intensity of shading as shown. (d) 50AZA upregulates ASL in
primary GBM 59 but not in primary GBM 6 cells. The top panel shows qPCR and the bottom panel MSP analysis of ASL in GBM 59 and GBM 6 cells with and without exposure
to 50AZA as indicated
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using the T98G cell line. Having confirmed knock down by
qPCR and western blotting (Figure 4a, upper panel), we
showed that reduced levels of ASS1 confer sensitivity to
ADI-PEG20 (Figure 4a, lower panel).
Arginine auxotrophic GBM CSCs are sensitive to
ADI-PEG20. The presence of CSCs in GBM is thought to
be associated with resistance to temozolomide and treat-
ment failure.6,28 Targeting these cells is therefore critical.
Using flow cytometry, we detected a population of stem cells
in the DBTRG GBM cell line (ASL methylated, partial
sensitivity to ADI-PEG20) using the putative stem cell
marker, CD133 (Figure 4b, upper panel). To test the effect
of ADI-PEG20 on the CD133þ component, sorted cells were
challenged with ADI-PEG20 and analysed for proliferation.
Both populations of cells were equally inhibited in the
presence of ADI-PEG20 (Figure 4b, lower panel).
Methylation of ASS1 sensitizes cells to autophagy upon
arginine deprivation. Previous studies have shown that
ADI-PEG20 induces autophagy in some ASS-negative cell
lines,22,29 but the relationship to epigenetic status is
unknown. As autophagy is a protective response to condi-
tions of nutrient deprivation, we were interested to determine
whether ADI-PEG20 was initially inducing an autophagic
response in GBM cells. To investigate this, cell lines were
exposed to ADI-PEG20 and analysed for markers of
autophagy by western blotting (upregulation of Beclin 1 and
the Atg genes 5 and 7, degradation of P62 and the
conversion of cytosolic LC3-1 to the lipidated form LC3-
1130) and acridine orange staining (formation of acidic
vesicular organelles). Acidic vesicular organelles are a
characteristic feature of autophagy and can be detected
and measured by vital staining with acridine orange, which
accumulates in these acidic compartments, and is detectable
as bright red fluoresence.31 Typical autophagic changes
were detectable as early as 6 h after ADI-PEG20 treatment
and progressively accumulated at 16 and 24 h in the ASS1-
methylated line LN229 only (Figure 4c). Similarly, acidic
vesicular organelles were only detected in this line and not in
the unmethylated line T98G (Figure 4d). Treatment with
bafilomycin A1, a specific inhibitor of vacuolar-type Hþ
ATPase, abrogated the formation of acidic vesicular
organelles and no fluorescence was observed (Figure 4d).
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Figure 3 Methylation in the ASS1 and ASL CpG islands blocks transcriptional upregulation upon arginine deprivation and confers arginine auxotrophy and sensitivity to
arginine deiminase (ADI-PEG20) in primary GBM explants. (a) Arginine deprivation induces ASS1 and ASL mRNA in primary GBM cells, but this is abrogated by CpG island
methylation. The indicated GBM explants were grown in the presence of ADI-PEG20 (1 mg/ml) or 50AZA (1 mM) as shown. RNA was harvested after 48 h and subjected to
qPCR analysis of ASS1 and ASL as indicated. Each experiment was performed at least twice and the values shown are means (þ / 1 SD) relative to untreated control cells.
(b) Western blot analysis of ASS in primary GBM cells. The indicated primary explants were grown in the presence of ADI-PEG20 (1 mg/ml) or 50AZA (1 mM) as shown. ASS
levels were analysed by western blotting after 48 h. Actin is used as a control protein. (c) Dose response curves for ADI-PEG20 in primary GBM of varying CpG island
methylation status. Logarithmic phase primary GBM cells were exposed to the indicated concentrations of ADI-PEG20 and proliferation assessed by measurement of SRB as
described in Methods. The most sensitive tumour is GBM 59 in which both ASS1 and ASL CpG islands are methylated and which is fully inhibited by 0.06mg/ml ADI-PEG20.
By contrast, GBM16 (ASS1 and ASL unmethylated) is unaffected by ADI-PEG20. GBM 27 and GBM 31 (either ASS1 or ASL CpG islands methylated) show intermediate
sensitivity to ADI-PEG20
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Chloroquine (CQ) inhibits autophagy and accelerates
ADI-PEG20 induced cell death. To test the hypothesis that
ADI-PEG20 induced autophagy is (at least initially) a survival
strategy for GBM cells, we investigated the effect of CQ, an
inhibitor of autophagy. CQ efficiently blocked ADI-PEG20-
induced p62 degradation and increased LC3-1 to LC3-11
conversion in the ASS1-methylated cell line LN229
(Figure 5a). These results are consistent with the fact that
CQ acts late in autophagy, resulting in the accumulation of
lipidated LC3-11. To further verify autophagy, stable LN229
cell lines expressing GFP-LC3 were generated to visualize
autophagosome formation in real time in live cells. During
autophagasome formation, GFP-LC3B is processed and
recruited to the autophagosome membrane where it can be
imaged as cytoplasmic puncta by high resolution fluores-
cence microscopy. Punctate GFP staining could be detected
in ADI-PEG20-treated cells, which accumulated in the
presence of CQ. This is consistent with the fact that CQ
inhibits autophagic flux of LC3 (Figure 5b). No punctate
staining was observed in GFP vector control cells.
To examine the effect of CQ on ADI-PEG20-induced cell
death, cells were treated with either or both CQ and
ADI-PEG20 and analysed by flow cytometry for sub-G1
content using propidium iodide. CQ accelerated and
enhanced ADI-PEG20-induced cell death in cells with
methylation in either the ASS1 or ASL CpG island as
evidenced by an increase in the sub-G1 compartment
(Figure 5c). By contrast, there was no effect of CQ in cells
lacking methylation in the ASS1 and ASL CpG islands
(Figure 5c). In methylated lines, cell death was first detectable
at 72 h following treatment with ADI-PEG20 alone. However,
in combination with CQ, cell death could be detected at 48 h.
By 72 h, CQ further increased ADI-PEG20-induced cell death
(Figure 5c).
Caspase inhibitors do not prevent ADI-PEG20-induced
cell death. To determine the role of caspases in ADI-
PEG20-induced cell death, a caspase inhibition assay was
performed. LN229 (ASS1 methylated) and T98G (ASS1 and
ASL unmethylated) cells were pre-treated with the pan
caspase inhibitor Z-VAD and then exposed to ADI-PEG20.
Cells were then harvested for assessment of caspase- and
non-caspase-mediated cell death by staining with FITC-
annexin and propidium iodide. Treatment of cells with Z-VAD
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Figure 4 ADI-PEG20 kills ASS1 knockdown cells, ASL negative CSCs and induces autophagy. (a) ASS1 knockdown cells are sensitive to ADI-PEG20. Stable ASS1
knockdown cells (T98G-A1) were exposed to ADI-PEG20 and analysed for proliferation as described in Methods. Cells containing empty vector were treated similarly. Upper
panel confirms knock down of ASS1 by qPCR and western blotting. T98G-A1 cells are more sensitive to killing than mock transfected cells, lower panel. (b) ADI-PEG20 kills
CD133-positive GBM cells. DBTRG cells (ASS1 unmethylated, ASL methylated) were sorted for CD133-positive cells (left histogram, IgG isotype control PE antibody; right
histogram, anti-CD133 showing 10.27% CD133-positive cells). CD133-positive and -negative fractions were then exposed to ADI-PEG20 (1mg/ml) and proliferation assessed
by SRB staining. CD133-positive and -negative fractions are equally sensitive to inhibition by ADI-PEG20, lower graph. (c and d) ADI-PEG20 induces autophagic markers.
LN229 and T98G cells were exposed to ADI-PEG20 (1 mg/ml) and analysed for autophagic markers by western blotting (upregulation of Beclin 1 and Atg proteins, degradation
of P62 and conversion of LC3-1 to LC3-11) (c) and by acridine orange staining (formation of acidic vacuoles) in the presence or absence of bafilomycin 48 h after treatment (d).
Autophagic changes are observed in the ASS1 methylated cell line, LN229, only. Bafilomycin abrogates the formation of acidic vacuoles, which stain red in the absence of
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alone had no effect on cell death in either LN229 or T98G
(Figure 5d). Caspase-independent cell death was observed
in LN229 (51%) but not T98G cells when pre-treated with
Z-VAD in the presence of ADI-PEG20. There was a higher
percentage of cell death in LN229 treated with ADI-PEG20
alone (78%), suggesting that 27% of cell death is attributable
to caspases.
ASS1 and ASL are frequent targets for epigenetic
inactivation in clinical cases of GBM. In order to translate
these results into the clinical setting, we examined the two
genes in clinical cases of human GBM using immunohis-
tochemistry, MSP and pyrosequencing. Previous studies on
ASS in melanoma, ovarian carcinoma and osteocarcinoma
showed focal expression in tumour tissue. There are no
published data on the expression of ASL in tumour tissue.
Sixty patients (36 male, 24 female, median age 57 years)
were retrospectively studied for ASS and ASL methylation
and, of these cases, 55 were evaluated for ASS expression
and 57 for ASL expression using a semi-quantitative scoring
system as described in Methods. Representative ASS and
ASL immunostaining and MSP in clinical cases are shown in
Figures 6b and d. The methylation status of primary cells
generated from some of these primary tumours is also shown
(Figure 6d). These primary lines were stained for GFAP, a
putative astrocyte marker and H&E stained (Figure 6a). All
cases were further characterized by staining for p53, IDH1
and EGFR, CD133 and MGMT methylation (data not shown).
In all, 13/55 samples were negative for ASS expression by
immunohistochemistry and scored 0. These negative cases
correlated well with MSP and pyrosequencing data. A further
15 cases were methylated by MSP and had pyrosequencing
values 45, an arbitrary cutoff for methylation positivity.
Eleven of these cases had low ASS staining (score 1),
whereas four cases exhibited strong ASS staining (score 2).
These results are represented in Supplementary Table S3.
Similarly for ASL, 5/57 stained negative (score 0) and
correlated with methylation. A further five showed no
correlation with methylation and immunohistochemistry. Eight
cases were positive for both ASS1 and ASL methylation
(Supplementary Table S3).
ASS1 and ASL CpG island methylation is a predictive
biomarker in GBM. To determine whether methylation of
ASS1 and/or ASL affects outcomes of patients, we carried
out a statistical analysis as described in Methods. Median
overall survival for GBM patients with unmethylated ASS1
CpG island was 496 days versus 309 days for patients with
methylated ASS1 CpG island (P¼ 0.11). Median overall
survival for patients with unmethylated ASL CpG island was
0
20
40
60
80
100
120
Un
tre
at
ed
z-
va
d-
fm
k 
AD
I-P
EG
20
z-
va
d-
fm
k 
+
AD
I-P
EG
20
%
 C
el
l V
ia
bi
lity
LN229
T98GCQ
ADI
-
-
+
-
+
+
LC3-1
LC3-11
P62
-
+
- ADI + ADI + CQI ADI + CQ
Actin
0
5
10
15
20
25
30
35
40
24 48 72
%
SU
B-
G
1
GBM31 (ASS1 Methylated)
0
5
10
15
20
25
30
24 48 72
%
 S
UB
-G
1
GBM 27 (ASL Methylated)
0
1
2
3
4
5
6
7
24 48 72
%
 S
UB
-G
1
GBM 16 (ASS1/ ASL Unmethylated)
0
10
20
30
40
50
24 48 72
%
 S
UB
-G
1
LN229 (ASS1 Methylated)
0
5
10
15
20
25
24 48 72
%
 S
UB
-G
1 Untreated
CQ
ADI-PEG20
CQ + ADI-PEG20
DBTRG (ASL Methylated)
LC
3-
G
FP
G
FP
Figure 5 Caspase-independent cell death is induced by ADI-PEG20 and is accelerated by chloroquine. (a) CQ inhibits autophagic markers. LN229 cells were treated with
1mg/ml ADI-PEG20 with and without 10 mg/ml CQ and analysed for conversion of LC3-1 to LC3-11 and degradation of P62 by western blotting 48 h post treatment. CQ inhibits
degradation of P62 and prevents autophagic flux as evidenced by accumulation of the LC3-11 band. (b) LN229 cells stably expressing GFP-LC3 or empty GFP vector were
treated as above and analysed for punctate, autophagosome-associated LC3-11 GFP by fluorescence microscopy. (c) Inhibition of autophagy accelerates and enhances ADI-
PEG20 induced cell death. Primary and GBM cell lines were treated with 10 mM CQ, 1 mg/ml ADI-PEG20 or in combination and analysed for sub G1 content by flow cytometry
at various time points. (Primary lines – GBM 31 ASS negative, GBM 27 ASL negative, GBM 16 ASS and ASL positive; GBM cell lines – LN229 ASS negative, DBTRG ASL
negative). CQ in combination with ADI-PEG20 accelerates and enhances cell death in ASS1/ASL negative lines only as evidenced by an increase in the sub-G1 compartment.
The results shown are mean values from three independent experiments. (d) Caspase inhibitors do not prevent ADI-PEG20-induced cell death. LN229 and T98G cells were
exposed to 1 mg/ml ADI-PEG20 and analysed for sub-G1 content as above. Where indicated, the caspase inhibitor Z-VAD-fmk was added to cells 24 h before addition of ADI-
PEG20. Results are expressed as the mean percentage of live cells remaining from three independent experiments. ADI-PEG20 has no effect on cell death in the
unmethylated cell line, T98G but induces marked cell death (78%) in the methylated line, LN229. The percentage of cell death induced by ADI-PEG20 is only partially blocked
by Z-VAD-fmk (51%)
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443 days compared with 299 days for patients with
methylated ASL CpG island (P¼ 0.16). Median overall
survival for patients whose GBM showed methylation in the
CpG islands of both ASS1 and ASL was significantly shorter
than those in whom neither CpG island was methylated or
only one of the two CpG islands was methylated. Median
overall survival in cases with either CpG island or none
methylated¼ 436 days versus 299 days (P¼ 0.0468)
(Figure 7).
ASS/ASL in non-neoplastic cells. Gliomas are character-
ized by a high number of non-neoplastic microglial cells
residing within and around the tumour. Previous studies on
rat microglia showed that ASS and ASL proteins are
upregulated in response to damage.24 We were interested
to determine the ASS1/ASL status of the infiltrating microglia
as they could effectively provide an exogenous source of
arginine for ASS/ASL-negative tumours and negate the
effect of ADI-PEG20 treatment. Tissue sections were stained
for Iba-1, a macrophage/microglia-specific surface antigen
and for ASS. No ASS staining was observed in Iba-1-positive
cells, suggesting that microglia within GBM do not/cannot
upregulate the ASS1 gene (Figure 6c).
Discussion
Despite advances in imaging and surgical techniques and the
use of temozolomide, GBM remains a universally and rapidly
fatal cancer, affecting patients of all ages. As such, the
requirement for novel therapeutic strategies is clear and
pressing. Here we show thatASS1 andASL, encoding the two
key enzymatic components of the arginine biosynthetic
pathway, are epigenetically regulated in glial brain tumours,
and we provide evidence that targeting of this pathway is a
novel therapeutic strategy for a subset of patients with this
disease. The importance of metabolic changes in brain
tumours has been recently illustrated by the detection of
gain-of-function mutations in isocitrate dehydrogenase in
oligodendrogliomas and the secondary GBM, which develop
from a subset of them.32 The present data show that arginine
metabolism is disrupted in a proportion of GBM, further
emphasizing that abnormalities in fundamental metabolic
pathways are a major feature of this disease. A key element of
our study is the use of low passage primary cultures of GBM
cells. These cultures are established in culture on the day of
surgical debulking, closely resemble the primary GBM from
which they were established in both expression and methyla-
tion of ASS1 and ASL and in their response to arginine
deprivation, analogous to established GBM cell lines and are
clearly a more appropriate model for pharmacological studies
than cell lines that have been maintained in culture for many
years.
We initially identified ASS1 as a transcriptionally down-
regulated gene in studies using the demethylating agent
50AZA to reverse methylation. A number of genes were
upregulated that have not been previously described as
epigenetically regulated in brain tumours specifically or, more
generally, in human cancer. These include, among others,
amino butyrate amino transferase (ABAT), EFEMP1 and
ZNF365. The significance of silencing of these genes and
their role (if any) in the pathogenesis of GBM awaits further
analysis.
We show, using two independent techniques (MSP and
pyrosequencing), that the ASS1 CpG island is aberrantly
methylated in 30% and the ASL CpG island in 22% of
GBM. Only a single study has previously demonstrated
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Figure 6 ASS and ASL in clinical cases of GBM. (a) Primary lines generated from tumour explants were stained for GFAP and hematoxylin and eosin. Representative
examples are shown. (b) Immunohistochemistry showing ASS and ASL in clinical cases of GBM. (c) Immunohistochemical analysis for the microglial marker, Iba-1, in ASS-
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methylation-dependent transcriptional silencing of ASS1 in
neoplasia, this in platinum-resistant epithelial ovarian can-
cer,21 but no previous study has examined expression and
epigenetic regulation of ASL. As such, ours is, to the best of
our knowledge, the first demonstration of epigenetic regula-
tion of this gene in human neoplasia. Silencing of ASS1
and ASL implies strong selective pressure to downregulate
the arginine biosynthetic pathway in GBM. Moreover, we
have shown that simultaneous methylation in the CpG
islands of both ASS1 and ASL occurs in 14% of GBM cases
in our series, further emphasizing that strong selective
pressure against cancer cells expressing the two genes must
operate in GBM.
In GBM cells lacking CpG island methylation, the mRNA of
bothASS1 andASL is upregulated by exposure to ADI-PEG20
and a similar upregulation is seen when cells are grown in
arginine-free culture medium (data not shown). Upregulation
of biosynthetic enzymes has been long recognized as a normal
physiological response to nutritional deprivation, for example,
under conditions of starvation.28,29 Here we show that CpG
island methylation blocks the adaptive transcriptional
response to arginine deprivation and it is this, rather than
absolute expression levels of ASS or ASL, that is the critical
determinant of cellular sensitivity to ADI-PEG20.
We demonstrate herein that ADI-PEG20 kills GBM cells
with ASS/ASL CpG island methylation predominantly inde-
pendently of caspase activation, suggesting that failure of
apoptosis will not be a barrier to successful therapy with ADI-
PEG20. Furthermore, inhibiting autophagy by CQ markedly
accelerated cell death by ADI-PEG20, implying that autop-
hagy triggered by ADI-PEG20 is initially a protective
response.
Trials of the clinical formulation of ADI-PEG20 are in
progress in advanced hepatocellular carcinoma, relapsed or
refractory small cell lung cancer and malignant pleural
mesethelioma (http://clinicaltrials.gov). A number of factors
from our work suggest that clinical trial of ADI-PEG20 in GBM
is merited. First, a major advantage of the proposed study in
GBM is that patients whose cancers exhibit methylation of
ASS1 and/or ASL can be further pre-tested for sensitivity to
ADI-PE20 in vitro using primary cultures to inform the
physician of likely treatment response. Such primary cultures
can be established efficiently, rapidly and with a high
probability of success from tissue obtained at biopsy or
primary debulking. Importantly, sufficient cells to allow
predictive pharmacological testing are available within a
credible time scale after surgery to inform the use of ADI-
PEG20. Second, the extremely unfavourable prognosis for
GBM patients correlates with intrinsic resistance to apoptosis
of GBM cells.4,5 Clinical trials of CQ in combination with
standard therapy showed some improvement in the survival of
GBM patients.30,31 Interestingly, the CQ derivatives quina-
crine and mefloquine show superior blood/brain penetration in
comparison to CQ and are more potent in vitro than CQ in
killing GBM cells,33 and we propose that combinations of ADI-
PEG20 with CQ or CQ derivatives merit consideration for
clinical trial in appropriate GBM patients. Third, recurrence of
GBM after therapy has been attributed to the presence of
chemo-/radio-resistant CD133þ CSCs.6 We have shown in
this work that in cells with methylated ASL, CD133þ GBM
cells are growth inhibited by ADI-PEG20 with the same
efficiency as CD133 , implying that the presence of chemo-/
radio-resistant CD133þ cells will not be a barrier to effective
therapy with ADI-PEG20 in vivo. Fourth, a major factor limiting
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effective management of GBM is the presence of the blood/
brain barrier, which may act to prevent efficient delivery of
chemotherapy into the brain. Clearly, as ADI-PEG20 exerts its
therapeutic effect by depletion of peripheral blood arginine,
passage across the blood/brain barrier is not required for
therapeutic efficacy of this agent. Based on these observa-
tions, we believe that clinical trial of arginine-deprivation
therapy with CQ or CQ derivative compounds is warranted in
GBM. CpG island methylation of either ASS1 or ASL, but
especially of ASS1 and ASL simultaneously, was associated
with particularly poor outcomes in patients treated with the
current gold-standard therapy of radiotherapy and temozolo-
mide. We have shown herein that GBM with CpG island of
methylation of both ASS1 and ASL are hypersensitive to ADI-
PEG20, implying that arginine depletion may be an appro-
priate therapy for patients with particularly poor prognosis
disease.
In conclusion, the data we present here identify a new
metabolic defect in GBM cells and suggest a novel therapeutic
strategy, which circumvents many of the traditional barriers to
effective management of this universally fatal malignancy.
Methods
Cell lines, primary cultures and clinical cases. Primary GBM cultures
were established from fresh tumours and maintained in DMEM/ F12 (1 : 1)
supplemented with 10% (foetal bovine serum). In brief, fresh tumour material was
washed in RPMI/F12 (1 : 1) and minced through a cell strainer to obtain a single-
cell suspension. Contaminating red blood cells were disrupted using sterile dH20
before cells were transferred to fresh growth medium. Primary cells were
expanded and early passage numbers were frozen in liquid N2 for analysis at a
later time point. Glioblastoma cell lines were obtained from the German tissue
bank (DSMZ) unless otherwise specified and maintained in RPMI (DBTRG),
DMEM (GAMG, SNB19, U87, U118, CCF, LN229), MEM (8MG, T87G), DMEM/
F12 (1 : 1) (MO59J, MO59K) or MEM/RPMI 1 : 1 (42MG) supplemented with 10%
foetal bovine serum (All purchased from Invitrogen, Paisley, UK) and 2mmol/l
L-glutamine (Sigma-Aldrich, Dorset, UK).
Sixty GBM cases selected from the Brain Tumour Registry at Imperial College
were selected for detailed analysis of enzymes in the arginine biosynthetic pathway.
Detailed clinical history, pre-and post-operative imaging and follow-up were
available in 60 cases. In all, 24 patients were female and 36 male with mean age 58
years and 7 months (range¼ 31 years and 1 month—83 years 11months; median
59 years 7 months). In each case, original H&E-stained sections were re-examined
to confirm the diagnosis, and the most representative samples were used for
immunohistochemical stains. Samples were obtained from surgical debulking rather
than stereotactic biopsies in order to examine as much tumour tissue as possible.
As such, we chose only supratentorial GBMs because gross total debulking is not
achievable in tumours occurring in the sub-cortical grey matter, cerebellum,
brainstem and spinal cord. Finally, we selected patients with a clinical history
consistent with a de novo GBM because almost all patients with secondary GBM
received treatment before debulking.
Methylation reversal. Cell lines and primary cultures were grown in the
presence of 5mM 50AZA (Sigma-Aldrich) for 7days. Fresh AZA was added with
every medium change and supplemented with 300 nM Trichostatin A (Sigma-
Aldrich) for the last 16 h of culture. Controls cells were treated with
dimethylsulphoxide.
Immunohistochemistry. Paraffin-embedded blocks were cut into 5mm
sections and dewaxed in xylene followed by rehydration in a standard alcohol
series. Antigen retrieval (for ASS) was achieved by pressure cooking for 20min in
citrate buffer (pH 6.0), followed by blocking of endogenous peroxidase in 0.3%
H202. Antibodies to ASS (BD Transduction, monoclonal, 25/ASS, 1 : 500, Oxford,
UK), ASL (Abnova, monoclonal, clone 4C5-1F2, 1 : 200, Heidelberg, Germany)
and Iba-1(rabbit polyclonal antibody, Wako, Osaka, Japan, 1 : 200) were added
and incubated overnight at 4 1C and developed using the Super Sensitive Polymer
HRP Detection System (BioGenex Laboratories, Inc., Fremont, CA, USA).
Expression of ASS/ASL was assessed semi-quantitatively where negative tumours
are defined as negative with expression ranging between 0–5% (score 0) and
diffuse (score 2) those showing expression in 75% or more tumour cells. Anything
in between negative and diffuse was defined focal and scored 1.
Analysis of gene expression in vitro. For qPCR, total RNA was
prepared from log phase cell lines and primary GBM cultures using the EZNA
isolation kit total RNA 1 according to the manufacturer’s instructions (VWR,
Leicester, UK). cDNA was synthesized from 1mg of total RNA using anchored
oligo(dT) primers and MMLV reverse transcriptase (Invitrogen).
Quantitative real-time reverse transcription–PCR (qPCR). All
primers were designed using Primer Express version 1.5a software (Life
Technologies Ltd, Paisley, UK). qPCR was performed with Syber Green fast mix
(Quanta Biosciences, Gaithersburg, MD, USA) using the Biorad CFX96 Detection
System instrument and software (Bio-Rad Laboratories Ltd, Hemel Hempstead,
UK). In all, 0.5ml cDNA was used per 20ml reaction with the following cycling
conditions: an initial denaturation at 95 1C for 3 min was followed by 40 cycles of
95 1C for 10 s, 55 1C for 30 s and 72 1C for 10 s. A melt curve analysis was
included as the final step, which consisted of temperature increments of 55–95 1C.
Each sample was analysed in triplicate and normalized to GAPDH. Primer
sequences for qPCR are given in Supplementary Table S1.
Western blot analysis. Whole-cell extracts were made using RIPA buffer
and the protein concentration of lysates estimated using a Bio-Rad Protein Assay
kit (Bio-Rad Laboratories Ltd, Hertfordshire, UK). Also, 10 mg cell extract was run
on a 10% SDS-acrylamide gel and transferred to a nylon membrane. The
membrane was blocked for 2 h at room temperature (PBS with 0.1% Tween
(PBST) and 5% milk powder) and probed using appropriate primary antibodies
(ASS1, clone 25; BD Biosciences, Oxford, UK, 1 : 2000 dilution, autophagy
antibody sampler kit, Cell Signaling Technology, Danvers, MA, USA) in 0.1%
Tween (PBST) and 5% milk powder overnight at 4 1C. After washing with 0.1%
Tween (PBST), the membrane was incubated in 0.1% Tween (PBST) and 5% milk
powder with a horseradish peroxidase–conjugated secondary antibody (1 : 2000
dilution, room temperature for 1 h). The secondary antibody was detected using
the ECL Plus Western Blotting Reagent (GE Healthcare, Life Sciences,
Buckinghamshire, UK).
Methylation analysis. Methylation of the ASS1 and ASL CpG islands was
analysed by MSP and quantitative pyrosequencing. Full maps of the ASS1 and
ASL CpG islands are presented in Supplementary Figure S1. Primers for MSP
were designed using MethPrimer software. Primer locations are shown in
Supplementary Figure S1 and sequences are listed in Supplementary Table S1.
Primers were designed to cover the entire region of the CpG island but only sets 1,
4, 5 and 7 were used for analysis of methylation (Supplementary Figure S1).
Bisulphite modification and MSP. Bisulphite conversion of genomic
DNA was carried out using the Zymo EZ DNA methylation kit (Genetix Ltd,
Hampshire, UK). This process converts unmethylated cytosine residues to uracil,
whereas methylated cytosine residues remain unchanged. MSP was then carried
out to determine the methylation status of ASS1 and ASL. In all, 5 ml of bisulphite-
modified DNA was used as templates for PCR reactions with primers specific for
methylated or unmethylated sequences. CpGenome Universal Methylated DNA
and CpGenome Universal Unmethylated DNA were used as positive and negative
controls, respectively. PCR conditions were as follows: 8 cycles of 95 1C for 2min,
51.7 1C for 30 s and 72 1C for 30 s were followed by 32 cycles of 95 1C for 30 s,
51.7 1C for 30 s and 72 1C for 30 s, then a final extension at 72 1C for 5min. PCR
products were electrophoresed through 2% agarose gels, stained with ethidium
bromide and visualized using a transilluminator.
Analysis of CpG methylation by pyrosequencing. Bisulphite-
modified genomic DNA (see above) was used as the template in pyrosequencing.
Modified DNA was then subjected to bisulphite sequencing. Biotage Sample Prep
kit and primers designed to amplify a 145 bp fragment across the CpG island of
ASS1 and ASL genes were optimized for software dedicated to methylation
analysis. After pyrosequencing, the analysis was performed using PyromarkID
Software (Biotage, Uppsala, Sweden). ASS1 forward 50-TGTGTTTATAATTTGGG
ATGG-30 and reverse 50-GGGTTTAGAGGAGGAGG-30 primers, ASL forward 50-
AGGATTGGAGGATGGAGGTAA-30 and reverse 50-CCACTAACCAAAACTTTTCT
AAC-30 primers. Annealing temperatures were 54 1C for ASS1 and 58 1C for ASL.
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Sensitivity of GBM cells to ADI-PEG20. Cell proliferation was
determined at various time points using the sulphorodamine B (SRB) assay
(Sigma-Aldrich). ADI-PEG20 was obtained from Polaris Pharmaceuticals Inc. (San
Diego, CA, USA) Arginine-free medium was purchased from MP Biomedicals
(Cambridge, UK). Cells were seeded in triplicate in 96-well plates at a density of
4 103 or 4 104 cells per well for cell lines or primary lines, respectively.
Twenty-four hours after seeding, the cells were washed 3 times in PBS and
cultured in medium containing varying concentrations of ADI-PEG20 (0–2mg/ml)
or in arginine-free medium supplemented with 1 mM citrulline and 2% dialysed
FCS for various time points. Cells were fixed with 10% tri-chloroacetate for at least
1 h at 4 1C, washed with distilled water and allowed to dry before being stained
with 0.4% SRB. The unbound SRB was washed with 0.1% acetic acid and the
plates allowed to air dry. Bound SRB was dissolved in 10mmol/l Tris pH 10.5 and
absorbances read at 495 nm.
Caspase inhibition assay. GBM cell lines were seeded at a density of
1.5 105 cells per well in 6-well tissue culture-treated plates. Once cells had
attached, they were then treated with or without 50 mM Z-VAD-fmk (Bachem,
Switzerland) for 24 h in order to inhibit caspase activity. Wells were then treated in
the following manner: control (untreated  /þ Z-VAD; citrulline 1 mM  /þ
Z-VAD; ADI-PEG20 (0.1mg/ml  /þ Z-VAD). Cells were then left for 48 h under
standard culture conditions and harvested for assessment of caspase and non-
caspase-mediated cell death. Floating and attached cells (removed by
trypsinisation) were then processed for flow cytometric analysis using the Annexin
V-FITC Apoptosis Detection kit (Calbiochem, Nottingham, UK). Flow cytometric
analysis was carried out using a Coulter EPICS flow cytometer (Beckman Coulter
(UK) Ltd, High Wycombe, UK) with FL1 for FITC-annexin staining and FL3 for
propidium iodide staining. Samples were analysed in duplicate and the
experiments were set up on three separate occasions.
Inhibition of autophagy. Cells were treated with 10 mM CQ, 1 mg/ml ADI-
PEG20 or both for 24, 48 and 72 h. Cells were harvested, washed in PBS and
resuspended in 500ml PBS and fixed by the addition of 2 ml of cold 90% methanol
for at least 2 h. After fixing, cells were washed twice in PBS and then
re-suspended in 300ml of PBS containing 1 mg/ml propidium iodide and 10mg/ml
RNaseA and then analysed by flow cytometry for sub-G1 population.
ASS1 knockdown. Short hairpin RNA (shRNA) sequences targeting ASS1
were cloned into the pSilencer 4.1-CMVpuro vector (Ambion, Life Technologies
Ltd). Sequences were designed by Ambion and supplied by Invitrogen
(Supplementary Table S1). Control vector expressing an shRNA sequence that
does not target any known human gene was used as a negative control in
experiments. T98G, U118 and 42MG cells were transfected with shRNA-
expressing vectors using Lipofectamine 1000 (Invitrogen). Stable pooled
populations of transfectants were obtained following selection with 1mg/ml
puromycin for 3–4 weeks.
Generation of stable GFP-LC3 cells. LN229 cells were transfected with
GFP-LC3 (CBA-401) expression vector or empty vector (Cambridge Bioscience,
Cambridge, UK). Stable pools of transfectants were obtained following selection
with 800 mg/ml of G418 for 3–4 weeks. These were expanded and stored in LN2
until required.
Flow cytometry for CD133 expression. For analysis of CD133
expression and cell sorting by flow cytometry, live cells were trypsinised, washed
with cold PBS/1%FCS (wash buffer) and re-suspended at a density of 1
106 cells/ml in wash buffer. In all, 1 105 cells were incubated with 100ml anti-
CD133 antibody or mouse IgG1 isotype matched control (Miltenyl Biotech Ltd
(Surrey, UK), diluted 1 : 100 in wash buffer) for 1 h at 4 1C. After the incubation
period, cells were washed twice in wash buffer incubated with 100ml goat-anti-
mouse FITC (Sigma-Aldrich) diluted 1 : 100 in wash buffer. Finally cells were
washed twice in wash buffer and re-suspended in 500ml PBS/FCS before being
analysed by flow cytometry and sorted for CD133-positive and -negative cells.
Statistics. Kaplan–Meier curves were used to estimate the probabilities of
survival and time to progression and the log-rank test to assess the statistical
significance of differences in event rates using Prism 5 (GraphPad software,
Inc.,La Jolla, CA, USA).
Written informed consent was received from the participants before inclusion in
the study.
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